Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Oct 3;17(10):3502-3510.
doi: 10.1080/21645515.2021.1924521. Epub 2021 Jun 8.

Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

Affiliations
Review

Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?

Selma Addou et al. Hum Vaccin Immunother. .

Abstract

Classical Hodgkin lymphoma is a neoplastic hematological disease. Standard first-line therapy, including chemotherapy and radiotherapy, is curative in >85% of early-stage patients, with a 5-year survival rate of >95%. However, approximately 15% of patients have hard-to-treat lymphoma with poor outcomes, and new treatment strategies are needed for these young adults. There are several well-documented cases in the medical literature on hematologic cancer remission following natural human viral infections. Therefore, hoping to reproduce these spontaneous tumor regressions, researchers have been investigating various viruses with oncolytic properties. There is a high rationale for using virotherapy in the treatment of Hodgkin lymphoma, in which tumor cells are often infected with the Epstein-Barr virus. Modern viral technologies and current knowledge about the relationship between viruses and cancer could accelerate the discovery of effective viral oncolytic therapies. This article reviews the use of oncolytic viruses as innovative therapies for treating Hodgkin lymphoma.

Keywords: Epstein-Barr virus; Hodgkin lymphoma; oncolytic viruses; virotherapy.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Mechanisms of action of oncolytic viruses as indicators of anti-tumoral activity in Hodgkin lymphoma
Figure 2.
Figure 2.
Choosing virotherapy for the treatment of relapsed and refractory classical Hodgkin lymphoma

Similar articles

References

    1. Molin D, Edström A, Glimelius I, Glimelius B, Nilsson G, Sundström C, Enblad G.. Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma. Br J Haematol. 2002;119(1):122–24. doi:10.1046/j.1365-2141.2002.03768.x. - DOI - PubMed
    1. Enblad G, Sundstrom C, Glimelius B.. Infiltration of eosinophils in Hodgkin’s disease involved lymph nodes predicts prognosis. Hematol Oncol. 1993;11(4):187–93. doi:10.1002/hon.2900110404. - DOI - PubMed
    1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th rev ed. IARC; 2017. Sep 18.
    1. Anagnostopoulos I, Hansmann M-L, Franssila K, Harris M, Harris NL, Jaffe ES, Han J, Van Krieken JM, Poppema S, Marafioti T, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood. 2000;96(5):1889–99. doi:10.1182/blood.V96.5.1889. - DOI - PubMed
    1. Lanzkowsky’s manual of pediatric hematology and oncology. 6th ed. [accessed 2021. Mar 13]. https://www.elsevier.com/books/lanzkowskys-manual-of-pediatric-hematolog....